Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
IMO interim financial results are meaningless. The sell off yesterday I think was from funds who are shortsighted and short sellers.Greg Williams believes in what he has and controls the company. My business sense says always follow the money
Logic tells me he thinks it is a good investment. If he wanted to take the company private, he is well over the 50% threshold already
I called the IR company and they said he has no intention of taking the company private at this time. However, that is all they can say.
I am surprised a potential suitor has not tried to buy SNGX
We are in agreement as to the potential of EYES.
This is reinforced by the continual insider purchase.
Insiders own about 76% of the shares and institutions about 7%
Short interest is over 4M shares. Retail has the rest
My experience in the market has told me not to trade or time the market. I would prefer to build a position & continue to add so that I become long term.
No one knows the catalyst that will get the stock rocketing. I do believe it will be before actual revenue.
GLTU
New form 4 just out...
Williams and trust bought at the mot Friday and today a total of about 50,000 shares.
Guess he puts his money where his mouth is Lol
ORION is the future as Argus is being fazed out. EYESW do not expire until 2024 so any purchase under 10 cents is very attractive IMO
With the addition of 25 new employee and additional funding that will be needed, EYES may remain under pressure. Since Greg Williams owns 73% of the shares and continues to buy, I only hope the company remains public until we see some big gains in the price
The Williams trust owns 78m of 124m shares of EYES
That is almost 63%
He can take the company private with 51%
Any thoughts as to why he continues to buy?
Will EYES go private. Perhaps ultimately
Greg Williams has owned more than 50% for a while now and continues to buy
why?
If he intends to go private soon, why continue to buy?
IMO he knows where the company is headed and that the stock is cheap
Second Sight Medical Products, Inc. (EYES) (“Second Sight” or the “Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, announced today that John T. Blake, Chief Financial Officer, will present at 20th Annual B. Riley FBR Investor Conference as follows:
Date: Thursday, May 23, 2019
Time: 3:30 P.M. Pacific Daylight Time
Location: the Beverly Hilton, Beverly Hills, CA
Webcast:
http://www.wsw.com/webcast/brileyfbr3/eyes
-- Positive Results of Early Feasibility Study and Significant
Market Potential Drive Refined Strategy --
-- Company to Provide Continued Support for Existing Argus® II Users Worldwide --
Second Sight Medical Products, Inc. (EYES) (“Second Sight” or the “Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced its plan to accelerate the development and commercialization of its Orion Visual Cortical Prosthesis System (“Orion”). Orion holds the potential to provide useful artificial vision to individuals blind from many causes, including glaucoma, eye injury, diabetic retinopathy, optic nerve disease or injury, and retinitis pigmentosa (“RP”).
“Given the positive results of our Early Feasibility Study, we believe that Orion offers the most effective and quickest path forward to treat nearly all forms of blindness and address a significant unmet need,” said Will McGuire, President and Chief Executive Officer of Second Sight. “After an extensive strategic review, we view Orion as a more attractive platform for continued investment and technological improvement that will extend our leadership position in artificial vision. We remain encouraged by our discussions with the U.S. Food and Drug Administration (“FDA”) regarding Orion’s regulatory path and are pleased by recent developments with the Centers for Medicare and Medicaid Services (CMS) regarding reimbursement for products approved via the FDA’s Breakthrough Devices program.”
“To support these initiatives, we intend to add more than 25 new positions this year, including top research and development talent as we pursue technological improvements of Orion. We are also taking steps to further align our organizational capabilities and focus resources primarily on advancing Orion as well as prepare for future sales volumes that we expect to be orders of magnitude greater than Argus II. Accordingly, we will suspend production of new Argus II systems in the near future as well as reduce ongoing commercial activities,” added McGuire.
“We remain committed to supporting existing Argus II users including pursuing regulatory approvals for the Argus 2s next-generation externals. Our commitment to artificial vision is further evidenced by our continued investment in multiple research projects designed to enhance the user experience, such as the integration of object or facial recognition and thermal imaging, with our technology,” concluded McGuire.
Gregg Williams, Chairman of the Board, added, “Orion provides a tremendous opportunity to further advance the field of artificial vision while also addressing the needs of millions of blind individuals globally. With encouraging early clinical results, we believe now is the right time for the Company to transition to the Orion platform and focus on accelerating our development and clinical programs. Second Sight will continue providing support to existing Argus users worldwide while repositioning our resources to accelerate the market introduction of Orion.”
About the Orion Visual Cortical Prosthesis System
Leveraging Second Sight’s 20 years of experience in neuromodulation for vision, the Orion® Visual Cortical Prosthesis System (Orion) is an implanted cortical stimulation device intended to provide useful artificial vision to individuals who are blind due to a wide range of causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. Orion is intended to convert images captured by a miniature video camera mounted on glasses into a series of small electrical pulses. The device is designed to bypass diseased or injured eye anatomy and to transmit these electrical pulses wirelessly to an array of electrodes implanted on the surface of the brain’s visual cortex, where it is intended to provide the perception of patterns of light. A six-subject early feasibility study of the Orion is currently underway at the Ronald Reagan UCLA Medical Center in Los Angeles and the Baylor College of Medicine in Houston. No peer-reviewed data is available yet for the Orion system. The Company anticipates enrolling additional feasibility subjects in 2019 while simultaneously negotiating the clinical and regulatory pathway to commercialization with the FDA as part of the Breakthrough Devices Program.
About Second Sight
Second Sight Medical Products, Inc. (EYES) develops, manufactures and markets implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals. A recognized global leader in neuromodulation devices for blindness, the Company is committed to developing new technologies to treat the broadest population of sight-impaired individuals. The Company’s U.S. headquarters are in Los Angeles, California, and European headquarters are in Lausanne, Switzerland. More information is available at www.secondsight.com.
hey Blue How you holding up?
Finally good news and more to come IMO
Surprised about Petit though
Stay strong
Nice surge last half hour on about 250k vol.
Second Sight Medical Products, Inc. (EYES), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, will release its financial results for the first quarter of 2019 on Wednesday, May 15, 2019, after the close of the U.S. financial markets.
Will McGuire, President and Chief Executive Officer, and John T. Blake, Chief Financial Officer, will host a conference call
The stock has been below the $1 threshold since 11/6/18
Do we expect news in less than 6 months to avoid a r/s?
The r/s is not the concern it is the cash. How much cash do they have before a raised is needed if you know
Thanks
Short interest is 4.6m shares.
Any good news will result in short squeeze IMHO
Insider buying has occurred on a daily basis for the past 2-3 weeks.
Some buying of warrants today as well
Do you think the r/s is inevitable?
ADXS board is no longer readible iggy
can you believe this stock is going lower?
the mkt cap is 13m
price is moving back to an appealing buy
Anyone interested?
Sold my position
GLTU
there was positive news this A.M. on PIII trial
I now think we face r/s in july if price stays so low
don't know what to think of SNGX
good news this A.M.
thought we were on our way but......
Anyone think we will retrace down?
Need some positive news
Annual meeting just announced
June 4th at 10:00AM PST
agree W is the buy at this time. We should get good exposure at the conference later today. The mkt. price might prohibit a recommendation from a real source. But, who knows if the data is that compelling we might hear from someone
Not really worried about the liquidity especially if we get over $1.47 the strike price
GLTAL
stock is strong even at the close
warrants moved to .25 also, thank you
I wonder if there was some short coverage in anticipation of some news. Over 4m shares short
GLTAL
stock has some good buying this A.M.
hopefully can get back over $1
warrants look cheap again - bought some at .19
Any thoughts on how the 1st qtr will look
Hopefully a catalyst to spring us forward
Zitry I actually use W as a trading vehicle. I sold my position at .25. My core holding is the common. Old school I guess LOL
Still adding common today and will purchase W if it pulls back to 16 or 17 cents
GLTU
very quiet on the message board and.....
the stock. Hope we will not face a R/S
Any comments?
So now we wait.....
1st qtr numbers won't be out for more than a month.
IMHO extreme patience will be needed to see real growth but rewards, hopefully big, will be seen
While I haven't seen the details of the earnings reaction has been lackluster after hours. Did you listen to the conf. call? I didn't see anything about it. Let's see what happens tomorrow
Second Sight Medical Products, Inc. (EYES), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind patients, will release its 2018 fourth quarter and year-end financial results on Wednesday, March 13, 2019, after the close of the U.S. financial markets.
Hope we see good numbers then and the 1st qtr
Any feeling as to when we might see some sales numbers?
1st qtr numbers s/b very telling IMHO
excellent points.....
One more thing about a potential R/S. Even if occurs, it will have little effect on the mkt. cap. since it will not be done in conjunction with a capital raise and the delusion, since funding seems to not be an issue.
What do you think is an attractive purchase price of EYESW?
Remember if the stock takes off in the future, the upside is limited since.....
EYESW can be called for redemption on 30 days’ notice if the Company’s common stock trades at $2.94 or higher for 15 consecutive trading days.
Will there be news before June 15th?
If we are still below $1, we will have a R/S
I concur with your assessment of the drop in price after the closing of the raise. You are aware that the warrants are callable?
The reason I invested is two fold, the technology and Mr. Williams
The big issue is when will we see real positive updates?
I wonder how long before a R/S will be required if we don't get back over $1?
We need good news soon IMHO
Anyone have a thought as to why we are going down this AM?
Anyone know when we will receive an update on the raise and whether Williams participated?